Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk

Current Cardiology Reports

Volumn 17, Issue 5, 2015, Pages

  Wharton, S ^a,b   Serodio, K J ^a  

^a Weight Management and Diabetes Management The Wharton Medical Clinic   (Canada)

^b YORK UNIVERSITY   (Canada)

Author keywords

Cardiometabolic risks; Medications; Weight management

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; AMFEBUTAMONE PLUS ZONISAMIDE; ANTIOBESITY AGENT; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LIRAGLUTIDE; LORCASERIN; LOW DENSITY LIPOPROTEIN; METRELEPTIN PLUS PRAMLINTIDE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; TESOFENSINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

BIRTH DEFECT; BLOATING; BLOOD PRESSURE REGULATION; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEADACHE; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS AND REGULATION; HUMAN; INJECTION SITE REACTION; INSOMNIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LONG TERM EXPOSURE; MALABSORPTION; MEDICAL HISTORY; METABOLIC ACIDOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; QUALITY OF LIFE; REVIEW; STEATORRHEA; STOMACH PAIN; VOMITING; WEIGHT CONTROL; WEIGHT REDUCTION; XEROSTOMIA; CLASSIFICATION; COMPLICATION; DRUG EFFECTS; RISK FACTOR;

ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; OBESITY; RISK FACTORS; WEIGHT LOSS;

EID: 84928347829     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-015-0590-z     Document Type: Review

References (65)

1. WHO. Obes. Overweight fact sheet. 2013. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 16 Oct 2014.
2. Herouvi D, Karanasios E, Karayianni C, et al. Cardiovascular disease in childhood: the role of obesity. Eur J Pediatr. 2013;172:721–32.
3. Rueda-Clausen CF, Padwal RS, Sharma AM. New pharmacological approaches for obesity management. Nat Rev Endocrinol. 2013;9:467–78.
4. Carter R, Mouralidarane A, Ray S, et al. Recent advancements in drug treatment of obesity. Clin Med. 2012;12:456–60.
5. Halford JCG. Pharmacotherapy for obesity. Appetite. 2006;46:6–10.
6. Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Ther Adv Chronic Dis. 2014;5:135–48.
7. Chan EW, He Y, Chui CSL, et al. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev. 2013;14:383–92.
8. Orexigen Therapeutics Inc. Orexigen press release 2013—Contrave and Empatic. 2013. 1–5. Available at: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1817249. Accessed 27 Oct 2014.
9. FDA. Contrave (naltrexone sr/bupropion SR combination): Advisory Committee Briefing Document. 2010;1–278.
10. Kennett GA, Clifton PG. New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav. 2010;97:63–83.
11. EMA. Guideline on clinical evaluation of medicinal products used in weight control. 2014;4:1–11.
12. FDA. Ephedrine alkaloid-containing dietary supplements. 2003. Available at: http://www.fda.gov/newsevents/testimony/ucm115044.htm. Accessed 2 Oct 2014.
13. Andraws R, Chawla P, Brown DL. Cardiovascular effects of ephedra alkaloids: a comprehensive review. Prog Cardiovasc Dis. 2005;47:217–25.
14. EMA. Press release: the European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. 2008;4–5.
15. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369:71–7.
16. Connolly H, Crary J, McGoon M, et al. Vaulvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581–8.
17. Sweeting AN, Tabet E, Caterson ID, et al. Management of obesity and cardiometabolic risk—role of phentermine / extended release topiramate. Diabetes Metab Syndr Obes. 2014;12:35–44.
18. Hainer V, Hainerová IA. Do we need anti-obesity drugs? Diabetes Metab Res Rev. 2012;28 Suppl 2:8–20.
19. EMA. European Medicines Agency recommends suspension of marketing authorisations for sibutramine. 2010;44:1–2.
20. Yanovski S, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311:74–86.
21. Sumithran P, Proietto J. Benefit-risk assessment of orlistat in the treatment of obesity. Drug Saf. 2014;37:597–608.
22. Torgerson J, Hauptman J, Boldrin M, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.
23. Erdmann J, Lippl F, Klose G, et al. Cholesterol lowering effect of dietary weight loss and orlistat treatment—efficacy and limitations. Aliment Pharmacol Ther. 2004;19:1173–9.
24. Ransom T, Goldenberg R, Mikalachki A, et al. Reducing the risk of developing diabetes. Can J diabetes. 2013;37 Suppl 1:S16–9.
25. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129:S102–38.
26. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015.
27. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330–42.
28. FDA. New Drug Application 22580- VI-0521 QNEXA (phentermine/topiramate). 2012;1–200. This report summarized MACE data and it was determined that there was no significant difference in the risk of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke between phentermine-topiramate and placebo.
29. Woloshin S, Schwartz L. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? JAMA Intern Med. 2014;174:615–9.
30. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52.
31. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine / topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study 1–3. 2012;297–308.
32. VIVUS. VIVUS Updates European Filing Strategy for Qsiva. 2013. 1–2. Available at: http://ir.vivus.com/releasedetail.cfm?ReleaseID=791927. Accessed 2 Oct 2014.
33. O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426–36.
34. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56.
35. EMA. Assessment report-Belviq. 2013;44:1–43.
36. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–77.
37. Eisai. Eisai Begins CAMELLIA-TIMI 61 LT outcomes study to assess cardiometa effects of lorcaserin HCI CIV in OW and OB pts. 2014;1–5. Available at: http://eisai.mediaroom.com/2014-02-24-Eisai-Begins-CAMELLIA-TIMI-61-Long-term-Outcomes-Study-to-Assess-Cardiovascular-and-Metabolic-Effects-of-Lorcaserin-HCI-CIV-in-Overweight-Obese-Patients. Accessed 28 Nov 2014.
38. FDA. FDA approves weight-management drug Contrave. 2014;1–4. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm413896.htm. Accessed 31 Oct 2014. This webpage provided some of the latest breaking news on Contrave FDA Approval. It also provided useful, publically available, information on study results and medication contraindications.
39. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21:935–43.
40. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.
41. Hollander P, Gupta A, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–9.
42. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19:110–20.
43. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268–78.
44. Novo Nordisk. Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo. 2014;1–4.
45. FDA. Highlight of prescribing information Victoza. 2010;1–23.
46. FDA. Approved diabetes medicines. 2014;1–4. Available at: http://www.fda.gov/forpatients/illness/diabetes/ucm408682.htm#collapse3. Accessed 29 Oct 2014.
47. FDA. FDA approves weight-management drug Saxenda. 2014. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427913.htm. Accessed 16 Mar 2015. This report concisely outlined the FDA approval of Saxenda.
48. Novo Nordisk. Novo Nordisk receives Health Canada approval for Saxenda® (liraglutide) for the treatment of chronic weight management. Available at: http://www.newswire.ca/en/story/1494067/novo-nordisk-receives-health-canada-approval-for-saxenda-liraglutide-for-the-treatment-of-chronic-weight-management#. Accessed 13 Mar 2015.
49. Novo Nordisk. Novo Nordisk reports 8 % weight loss in phase 3a obesity trial with liraglutide 3 mg. 2013;24–26.
50. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–16.
51. Wadden T, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37:1443–51. This SCALE trial found numerous positive cardiometabolic effects of liraglutide 3.0 mg and is one of the defining studies used to assess the safety of liraglutide for weight management.
52. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84–90.
53. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–81.
54. Zinman B, Gerich J, Buse J, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224–30.
55. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046–55.
56. Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res. 2011;8:237–40.
57. George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014;19:65–76.
58. Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1906–13.
59. Orexigen Therapeutics Inc. Orexigen receives three month extension of FDA NB32. 2014:1–2. Available at: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1938944. Accessed 15 Oct 2014.
60. Jackson VM, Price DA, Carpino PA. Investigational drugs in phase II clinical trials for the treatment of obesity: implications for future development of novel therapies. Expert Opin Investig Drugs. 2014;23:1055–66.
61. Gadde KM, Yonish GM. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. 2007;1227–30.
62. Orexigen Therapeutics Inc. Emaptic. 2014. Available at: http://www.orexigen.com/programs/empatic.html. Accessed 26 Nov 2014. This web page outlined some of the only available data on the effectiveness of Empatic (bupropion-zonisamide slow-release compound) a promising weight management medication undergoing phase III clinical testing.
63. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. 2009;17:1736–43.
64. Tam CS, Lecoultre V, Ravussin E. Novel strategy for the use of leptin for obesity therapy. Expert Opin Biol Ther. 2011;11:1677–85.
65. PR Newswire, source Amylin Pharmaceuticals Inc. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity. 2009. Available at: http://www.prnewswire.com/news-releases/amylin-pharmaceuticals-announces-positive-results-from-dose-ranging-clinical-study-of-pramlintidemetreleptin-combination-treatment-for-obesity-62158697.html. Accessed 16 Mar 2014.